<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mice lacking factor XII (fXII) or factor XI (fXI) are resistant to experimentally-induced <z:mp ids='MP_0005048'>thrombosis</z:mp>, suggesting fXIIa activation of fXI contributes to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>It is not clear whether this reaction has relevance for <z:mp ids='MP_0005048'>thrombosis</z:mp> in pri mates </plain></SENT>
<SENT sid="2" pm="."><plain>In 2 carotid artery injury models (FeCl(3) and <z:chebi fb="0" ids="52261">Rose Bengal</z:chebi>/laser), fXII-deficient mice are more resistant to <z:mp ids='MP_0005048'>thrombosis</z:mp> than fXI- or factor IX (fIX)-deficient mice, raising the possibility that fXII and fXI function in distinct pathways </plain></SENT>
<SENT sid="3" pm="."><plain>Antibody 14E11 binds fXI from a variety of mammals and interferes with fXI activation by fXIIa in vitro </plain></SENT>
<SENT sid="4" pm="."><plain>In mice, 14E11 prevented <z:mp ids='MP_0006134'>arterial occlusion</z:mp> induced by FeCl(3) to a similar degree to total fXI deficiency </plain></SENT>
<SENT sid="5" pm="."><plain>14E11 also had a modest beneficial effect in a tissue factor-induced <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> model, indicating fXI and fXII contribute to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation even when factor VIIa/tissue factor initiates <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>In baboons, 14E11 reduced platelet-rich <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> growth in collagen-coated grafts inserted into an arteriovenous shunt </plain></SENT>
<SENT sid="7" pm="."><plain>These data support the hypothesis that fXIIa-mediated fXI activation contributes to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in rodents and primates </plain></SENT>
<SENT sid="8" pm="."><plain>Since fXII deficiency does not impair hemostasis, targeted inhibition of fXI activation by fXIIa may be a useful antithrombotic strategy associated with a low risk of <z:mp ids='MP_0001914'>bleeding</z:mp> complications </plain></SENT>
</text></document>